How Declining Sales At Surgery Partners (SGRY) Has Changed Its Investment Story

• Surgery Partners has faced softer unit volumes over the past two years, a projected decline in sales over the next 12 months, and rising interest costs on floating-rate debt that complicate its margin recovery efforts.
• The combination of weaker demand trends, a high forward P/E multiple, and elevated net-debt-to-EBITDA has raised concerns about leverage and the potential need for shareholder dilution to support the balance sheet.
• The next step is an assessment of how Surgery Partners' investment narrative holds up when confronted with slowing sales and a stretched balance sheet.

Scan beyond Surgery Partners and assess other hospital and outpatient operators managing leverage and valuation by reviewing our list of solid balance sheet and fundamentals (25 results).

Surgery Partners Investment Narrative Recap

For Surgery Partners, the core belief is that outpatient procedures keep migrating from hospitals into its centers and that management can convert that volume into healthier cash generation despite softer unit trends. The recent commentary around weaker sales and a pressured payer mix keeps the focus squarely on near term case volumes and mix quality rather than long term story lines.

The key near term catalyst is whether Surgery Partners can stabilize sales while protecting margins against rising interest costs on floating rate debt. The biggest risk is that softer revenue, a high forward P/E and elevated leverage combine to slow deleveraging, which could make any equity raise more painful for existing shareholders.

The DCF work suggesting Surgery Partners trades below estimated future cash flow value is central to this debate. That view depends on the business eventually translating its network of outpatient facilities into stronger free cash generation, even though consensus currently points to revenue declining over the next three years while earnings move from a loss toward profitability.

That gap between a modeled intrinsic value and the current share price only matters if execution on volume, reimbursement and cost control keeps tracking toward the cash flow profile in those forecasts. Any further drag from interest expense, slower acquisitions or choppy portfolio optimization would directly weigh on that path and could delay the very catalyst some investors are watching.

Surgery Partners' current analyst narrative points to revenue of US$4.0b and earnings of US$72.9m by 2029. That outlook assumes revenue growth of 5.9% per year and an earnings swing of about US$149m from a loss of US$76.1m today to the forecast profit.

Uncover why Surgery Partners' fair value indicates a 29% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

One alternate view puts leverage risk front and center for Surgery Partners. The most cautious analysts were working off revenue of about US$3.8b and earnings of US$229.9m by 2029, tied to a US$14.0 price target. That is a far more restrained story, and the latest news could easily push these narratives to reset.

Explore 2 other Surgery Partners fair value estimates, including one that suggests there may be as much as 10% downside from the current price.

Form Your Own Verdict

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Surgery Partners research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for Surgery Partners. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Surgery Partners' overall financial health at a glance.

Looking For More Investment Ideas Beyond Surgery Partners?

Once you have a handle on Surgery Partners, it can help to widen the lens and compare it with other businesses that balance quality, resilience and valuation using the Simply Wall St Screener.

• If you want potential mispricing on your side, you can start with companies that pair strong fundamentals with appealing valuations through the 29 high quality undervalued stocks.
• For investors who care about capital preservation first, you can focus on resilient businesses with sturdy financial footing using the 31 resilient stocks with low risk scores.
• If you are hunting for under-the-radar opportunities, you can scan a 20 high quality undiscovered gems that may not yet be widely followed by the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com